NA
FDMT icon

NewEdge Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

NewEdge Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82K Hold
212
– – ﹤0.01% 3856
2026
Q1 		$1.97K Hold
212
– – ﹤0.01% 3815
2025
Q4 		$1.59K Hold
212
– – ﹤0.01% 3922
2025
Q3 		$1.84K Buy
+212
New +$1.27K ﹤0.01% 3790

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

NewEdge Advisors's FDMT Position: Q2 2026 in Review

NewEdge Advisors held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 212 shares worth $2.82K. The position accounts for ﹤0.01% of the portfolio, ranked #3856.

NewEdge Advisors first reported a position in FDMT in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • NewEdge Advisors held 212 shares of 4D Molecular Therapeutics worth $2.82K as of Q2 2026.
  • NewEdge Advisors left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3856 holding.
  • NewEdge Advisors first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.